Study characteristics and intervention.

*<p>Unless on risk assessment deemed to be a high-shedder, where contact precautions would be used (but rarely enacted).</p

PFGE subtypes.

<p>PFGE subtypes.</p

Segmented regression model. Incidence of MRSA per 1000 at risk patient days in ICU over the study period.

<p>There was a decline in MRSA acquisition of 7% per month in the intervention phase, which was a significant change in slope compared with the control phase (95% CI for change in slope 1.9 to 12.8% reduction). The dark blue lines are the data, the black lines are the model best fit results and the light blue lines are the upper and lower values of the 95% credible intervals for the model estimates.</p

Swab results.

*<p>Patients at risk.</p>**<p>Days at risk.</p><p>Denominators may vary if data were missing.</p

Patient characteristics.

*<p>Patients were in contact precautions or single room/cohorted for reasons other than MRSA.</p><p>Denominators may vary if data were missing.</p

Hazard ratios for covariates associated with MRSA acquisition.

<p>Hazard ratios for covariates associated with MRSA acquisition.</p

Focus group participant details.

Focus group participant details.</p

Representative quotations from Theme 2 reflecting ‘Psychological Capability’ of the COM-B model.

Representative quotations from Theme 2 reflecting ‘Psychological Capability’ of the COM-B model.</p

Representative quotations from Theme 4, reflecting ‘Physical Opportunity’ of the COM-B model.

Representative quotations from Theme 4, reflecting ‘Physical Opportunity’ of the COM-B model.</p

Recommendations for change to optimise appropriate SAP decision-making and prescribing.

Recommendations for change to optimise appropriate SAP decision-making and prescribing.</p